본문 바로가기

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
SCIENTIFIC REPORTS9 · 2019
피인용
Web of Science 11Scopus 13
FWCI (Scopus)
0.42
JCR IF
JCR 2018 4.011
ISSN
2045-2322

저자

  1. Hong, Jung Yong제1저자Department of Oncology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea
  2. Yoon, Dok HyunDepartment of Oncology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea
  3. Yoon, Sang EunDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  4. Kim, Seok JinDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  5. Lee, Ho SupDepartment of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea
  6. Eom, Hyeon-SeokCenter for Hematologic Malignancies, National Cancer Center, Goyang, Republic of Korea
  7. Lee, Hye WonCenter for Hematologic Malignancies, National Cancer Center, Goyang, Republic of Korea
  8. Shin, Dong-YeopDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
  9. Koh, YoungilDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
  10. Yoon, Sung-SooDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
  11. Jo, Jae-CheolDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
  12. Kim, Jin SeokDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
  13. Kim, Soo-JeongDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
  14. 조수희Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea
  15. Lee, Won-SikDepartment of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Gaegumdong, Busanjingu, Busan, Republic of Korea
  16. Won, Jong-HoDivision of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
  17. Kim, Won SeogDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  18. Suh, Cheolwon교신저자Department of Oncology, Asan Medical Center, Ulsan University College of Medicine, Seoul, Republic of Korea

초록

Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin's lymphomas with poor clinical outcomes. Pralatrexate showed efficacy and safety in recurrent or refractory PTCLs. The purpose or this study was to investigate the efficacy and safety of pralatrexate in relapsed or refractory PTCLs in real-world practice. This was an observational, multicenter, retrospective analysis. Between December 2012 and December 2016, a total of 38 patients with relapsed or refractory PTCLs were treated with pralatrexate at 10 tertiary hospitals in Korea. Patients received an intravenous infusion of pralatrexate at a dose of 30 mg/m(2)/week for 6 weeks on a 7-week schedule. Modified dosing and/or scheduling was allowed according to institutional protocols. Median patient age was 58 years (range, 29-80 years) and the most common subtype was peripheral T-cell lymphoma, not otherwise specified (n = 23, 60.5%). The median dosage of pralatrexate per administration was 25.6 mg/m(2)/wk (range, 15.0-33.0 mg/m(2)/wk). In intention-to-treat analysis, 3 patients (7.9%) showed a complete response and 5 patients (13.2%) showed a partial response, resulting in an overall response rate (ORR) of 21.1%. The median duration of response was 7.6 months (range, 1.6-24.3 months). The median progression-free survival (PFS) was 1.8 months (95% confidence interval [CI], 1.7-1.8 months) and the median overall survival was 7.7 months (95% CI, 4.4-9.0 months). The most common grade 3/4 adverse events were thrombocytopenia (n = 13, 34.2%), neutropenia (n = 7, 23.7%), and anemia (n = 7, 18.4%). Our study showed relatively lower ORR and shorter PFS in patients with recurrent or refractory PTCLs treated with pralatrexate in real-world practice. The toxicity profile was acceptable and manageable. We also observed significantly lower dose intensity of pralatrexate in real-world practice.

키워드

REVEALS MARKED ACTIVITYPIVOTAL PHASE-IIRESPONSE CRITERIAWORKSHOP

식별자

Scopus EID
2-s2.0-85077199256
WoS UID
000508984900021